Tuesday September 19th 2017

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

Summary During the last two decades, treatment options for patients with multiple sclerosis (MS) have broadened tremendously. All agents that are currently approved for clinical use have potential side effects, and a careful risk–benefit evaluation is part of a decision algorithm to identify the optimal treatment choice for an individual patient. Whereas glatiramer acetate and interferon beta preparations have been used in MS for decades and have a proven safety record, more recently approved drugs appear to be more effective, but potential risks might be more severe. The potential complications of some novel therapies might not even have been identified to their full extent. This review is aimed at the clinical neurologist in that it offers insights into potential adverse events of each…

See more here: 

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

Leave a Comment

More from category

Scientists discover markers for progressive multiple sclerosis
Scientists discover markers for progressive multiple sclerosis

Scientists have uncovered two closely related cytokines -- molecules involved in cell communication and movement -- [Read More]

Study uncovers markers for severe form of multiple sclerosis
Study uncovers markers for severe form of multiple sclerosis

Scientists have uncovered two molecules involved in cell communication and movement that may explain why some people [Read More]

Costly drugs to weigh on U.S. employers’ expenses in 2018: survey
Costly drugs to weigh on U.S. employers’ expenses in 2018: survey

(Reuters) - U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat [Read More]

TG Therapeutics commences enrolment for Phase III multiple sclerosis trials
TG Therapeutics commences enrolment for Phase III multiple sclerosis trials

US-based biopharmaceutical firm TG Therapeutics has commenced enrolment for the Phase III ULTIMATE clinical programme [Read More]

Therapy could offer new hope for MS patients
Therapy could offer new hope for MS patients

Multiple sclerosis sufferer Roy Palmer and his wife Helen (pictured) are desperate for him to be able to walk again. [Read More]